IRL’s drug discovery platform, the Integrative Screening Process (ISP), and an application, has been published in ACS Chemical Neuroscience

January 24, 2017

The ISP approach is exemplified in this publication by assessing a new class of CNS active compounds, the dopidines, compared to other monoamine modulating compounds including antipsychotics, antidepressants, and procognitive agents. In addition, the discovery and classification of IRL790 and IRL752 by ISP is described. The results support the utility of ISP as a powerful tool for drug discovery. The distinct phenotypic, and novel, profiles of IRL790 and IRL752 warrant further clinical investigations.